Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Abemaciclib + Ramucirumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Abemaciclib||Verzenio||LY2835219||CDK4/6 Inhibitor 9||Verzenio (abemaciclib) is a dual CDK4/6 inhibitor, which inhibits Rb1 protein phosphorylation and may induce cell cycle arrest and prevent growth in cancer cells (PMID: 24919854). Verzenio (abemaciclib) is FDA approved as a monotherapy and in combination with Faslodex (fulvestrant) in patients with hormone receptor-positive (ESR, PGR) and ERBB2 (HER2) receptor-negative advanced or metastatic breast cancer (FDA.gov).|
|Ramucirumab||Cyramza||LY3009806||VEGFR2 Antibody 4||Cyramza (ramucirumab) is a monoclonal antibody, which binds and inhibits VEGFR2 (KDR) resulting in decreased angiogenesis (PMID: 24094768). Cyramza (ramucirumab) is FDA approved for use as a monotherapy or in combination with paclitaxel in patients with gastric or gastroesophageal junction adenocarcinoma who progressed on chemotherapy, in combination with erlotinib as first-line therapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletion mutations or L858R, in combination with decetaxel in patients with NSCLC who progressed on prior therapy, in combination with FOLFIRI in patients with colorectal cancer who progressed on prior therapy, and as monotherapy in patients with hepatocellular carcinoma who have received sorafenib (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung non-small cell carcinoma||not applicable||Abemaciclib + Ramucirumab||Phase Ib/II||Actionable||In a Phase Ib trial, the combination of Verzenio (abemaciclib) and Cyramza (ramucirumab) was well-tolerated and demonstrated preliminary activity in patients with previously treated metastatic non-small cell lung cancer, resulting in a response rate of 5% (2/39; all partial responses (PR)), a disease control rate of 54% (21/39; 2 PR and 19 stable disease), and a median progression-free survival of 4.83 months (95% CI, 2.60, 6.93) (PMID: 30082474; NCT02079636).||30082474|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02745769||Phase I||Merestinib + Ramucirumab Abemaciclib + Ramucirumab||A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents||Completed|